Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 10:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 1,656 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Growth Clear all
Completed Phase 2 Interventional Results available

PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma

NCT00049530
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
PEG-interferon alfa-2b
Biological
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
32
States / cities
Birmingham, Alabama • Lakeland, Florida • Bloomington, Illinois + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 24, 2026, 10:53 PM EDT
Recruiting Phase 2 Interventional

Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)

NCT06698250
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Zanzalintinib, Durvalumab, Tremelimumab
Drug
Lead sponsor
Anwaar Saeed
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania • Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 24, 2026, 10:53 PM EDT
Completed Phase 2 Interventional

Sandostatin LAR Depot vs. Surgery for Treating Acromegaly

NCT00001860
View directory record Official record
Conditions
Acromegaly, Pituitary Neoplasm
Interventions
Sandostatin LAR Depot versus transsphenoidal surgery
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 24, 2026, 10:53 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Pregnancy 24/7 Offspring Study

NCT07172880
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
Kara Whitaker
Other
Eligibility
0 Years to 47 Years
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
3
States / cities
Iowa City, Iowa • Pittsburgh, Pennsylvania • Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 24, 2026, 10:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Probiotic Formula and Infant Growth

NCT01476397
View directory record Official record
Conditions
Healthy
Interventions
Control infant formula, Test infant formula
Other
Lead sponsor
Société des Produits Nestlé (SPN)
Industry
Eligibility
11 Days to 17 Days
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
8
States / cities
Scottsdale, Arizona • Marietta, Georgia • Bardstown, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2014 · Synced Oct 24, 2026, 10:53 PM EDT
Recruiting Phase 1 Interventional

Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma

NCT06934889
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
ERAS-801, ABBV-637, ABBV-155, Temozolomide, Radiotherapy
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
11
States / cities
Los Angeles, California • Miami, Florida • Indianapolis, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 24, 2026, 10:53 PM EDT
Completed Not applicable Interventional Results available

Growth Hormone Treatment on Phosphocreatine Recovery in Obesity

NCT01421589
View directory record Official record
Conditions
Obese, Growth Hormone Secretion Abnormality
Interventions
Growth hormone treatment
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 1, 2014 · Synced Oct 24, 2026, 10:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Pesticide Exposure on Neurodevelopment/Growth/Respiratory Health

NCT00021658
View directory record Official record
Conditions
Environmental Exposure
Interventions
Pesticide application procedures
Procedure
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years and older · Female only
Enrollment
550 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2003
U.S. locations
1
States / cities
Salinas, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2014 · Synced Oct 24, 2026, 10:53 PM EDT
Completed Not applicable Interventional

Formula for Children With Cow's Milk Allergy

NCT02317952
View directory record Official record
Conditions
Milk Allergy
Interventions
Experimental Extensively Hydrolyzed Formula, Active Comparator Formula
Other
Lead sponsor
Perrigo Nutritionals
Industry
Eligibility
Up to 13 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
18
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Huntington Beach, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Oct 24, 2026, 10:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Oral Health With Serious Games

NCT02027597
View directory record Official record
Conditions
Caries, Tooth Decay, Cavities, Gingivitis
Interventions
Attack of the S. Mutans, Follow-up, SnowWorld
Other
Lead sponsor
University of Washington
Other
Eligibility
8 Years to 12 Years
Enrollment
161 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 24, 2026, 10:53 PM EDT
Completed Phase 2 Interventional Results available

A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer

NCT00913835
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
Olaratumab, liposomal doxorubicin
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
6
States / cities
Joliet, Illinois • Indianapolis, Indiana • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Oct 24, 2026, 10:53 PM EDT
Completed No phase listed Observational

Acute Side Effects in Patients Who Are Undergoing Stereotactic Radiosurgery for Brain Tumors or Other Brain Disorders

NCT00255671
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Metastatic Cancer, Radiation Toxicity
Interventions
Questionnaire
Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 24, 2026, 10:53 PM EDT
Completed Phase 2 Interventional Results available

A Safety and Efficacy Study of 2 Dosing Regimens of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution Compared With Vehicle in Patients With Dry Eye Disease.

NCT06244316
View directory record Official record
Conditions
Dry Eye Disease
Interventions
rhNGF 5 μg/mL, rhNGF 10 μg/mL, Vehicle (Placebo solution)
Drug
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
10
States / cities
Chandler, Arizona • Torrance, California • Colorado Springs, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 24, 2026, 10:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Eyelash Growth From Application of Bimatoprost in Gel Suspension to the Base of the Eyelashes

NCT00773136
View directory record Official record
Conditions
Hypertrichosis
Interventions
Bimatoprost Suspension
Drug
Lead sponsor
University of Miami
Other
Eligibility
20 Years to 90 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 16, 2014 · Synced Oct 24, 2026, 10:53 PM EDT
Completed Not applicable Interventional

Preterm Infant Growth

NCT01162798
View directory record Official record
Conditions
Growth, Development, Infant
Interventions
infant formula, control infant formula
Other
Lead sponsor
Société des Produits Nestlé (SPN)
Industry
Eligibility
Up to 1 Month
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
9
States / cities
Oakland, California • Park Ridge, Illinois • Iowa City, Iowa + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2014 · Synced Oct 24, 2026, 10:53 PM EDT
Completed Phase 1 Interventional

Phase I Chemoprevention Trial With Green Tea Polyphenon E & Erlotinib in Patients With Premalignant Lesions of the Head & Neck

NCT01116336
View directory record Official record
Conditions
Cancer of Head and Neck, Neoplasms, Head and Neck
Interventions
Erlotinib, Green Tea Polyphenon E
Drug · Dietary Supplement
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
3
States / cities
Atlanta, Georgia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Oct 24, 2026, 10:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sexually Dimorphic Effects of GHRH in Adult Growth Hormone Testing

NCT00324064
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
GHRH/arginine stimulation testing
Procedure
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
5 Years to 40 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 5, 2010 · Synced Oct 24, 2026, 10:53 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

NCT03280563
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody, Bevacizumab, Entinostat, Exemestane, Fulvestrant, Ipatasertib, Tamoxifen, Abemaciclib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
14
States / cities
Birmingham, Alabama • San Francisco, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 24, 2026, 10:53 PM EDT
Completed Not applicable Interventional

Evaluation of Infants Fed an Extensively Hydrolyzed Infant Formula

NCT03884309
View directory record Official record
Conditions
Protein Intolerance
Interventions
Experimental Hydrolyzed Protein Infant Formula
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
Up to 60 Days
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
College Park, Georgia • Nicholasville, Kentucky • Lincoln, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 24, 2026, 10:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Recombinant Human Platelet-derived Growth Factor in Combination With Collagen Matrix

NCT04462237
View directory record Official record
Conditions
Gingival Recession, Platelet Derived Growth Factor
Interventions
Root coverage procedures
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Oct 24, 2026, 10:53 PM EDT
Completed Phase 2 Interventional

Phase II Study of Growth Hormone in Children With Cystic Fibrosis

NCT00016445
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
growth hormone
Drug
Lead sponsor
University of Utah
Other
Eligibility
5 Years to 12 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
9
States / cities
Phoenix, Arizona • Orange, California • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2008 · Synced Oct 24, 2026, 10:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects on Growth and Tolerance of a Routine Infant Formula Fed to Term Infants

NCT02132663
View directory record Official record
Conditions
Growth of Term Infants
Interventions
Control: Marketed routine infant formula, An investigational infant formula containing an alternate source of DHA
Other
Lead sponsor
Mead Johnson Nutrition
Industry
Eligibility
10 Days to 14 Days
Enrollment
315 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
22
States / cities
Birmingham, Alabama • Dothan, Alabama • Pinson, Alabama + 18 more
Source: ClinicalTrials.gov public record
Updated May 1, 2015 · Synced Oct 24, 2026, 10:53 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment

NCT06668805
View directory record Official record
Conditions
Noonan Syndrome
Interventions
Vosoritide Injection
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
3 Years to 11 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2041
U.S. locations
21
States / cities
Los Angeles, California • Orange, California • Aurora, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 24, 2026, 10:53 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Lantus and Neutral Protamine Hagedorn (NPH) Insulin in the Dawn Phenomenon

NCT00694122
View directory record Official record
Conditions
Type 1 Diabetes, Dawn Phenomenon
Interventions
Lantus (glargine)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2014 · Synced Oct 24, 2026, 10:53 PM EDT